FOLD
Amicus Therapeutics Inc. Healthcare - Biotechnology Investor Relations →
Amicus Therapeutics Inc. (FOLD) closed at $14.43 as of 2026-03-20, trading 34.2% above its 200-week moving average of $10.75. The stock moved further from the line this week, up from 34.1% last week. With a 14-week RSI of 98, FOLD is in overbought territory.
Over the past 14 weeks, up-weeks have carried more volume than down-weeks (2.18 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.
Over the past 933 weeks of data, FOLD has crossed below its 200-week moving average 19 times. On average, these episodes lasted 30 weeks. Historically, investors who bought FOLD at the start of these episodes saw an average one-year return of +0.8%.
With a market cap of $4.5 billion, FOLD is a mid-cap stock. The company generates a free cash flow yield of 1.1%. Return on equity stands at -11.6%. The stock trades at 16.4x book value.
Share count has increased 10.6% over three years, indicating dilution.
Over the past 17.9 years, a hypothetical investment of $100 in FOLD would have grown to $139, compared to $644 for the S&P 500. FOLD has returned 1.8% annualized vs 11.0% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: FOLD vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After FOLD Crosses Below the Line?
Across 19 historical episodes, buying FOLD when it crossed below its 200-week moving average produced an average return of +0.2% after 12 months (median -5.0%), compared to +18.9% for the S&P 500 over the same periods. 37% of those episodes were profitable after one year. After 24 months, the average return was +18.6% vs +36.0% for the index.
Each line shows $100 invested at the moment FOLD crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
FOLD has crossed below its 200-week MA 19 times with an average 1-year return of +0.8% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 2008 | Jul 2008 | 9 | 20.8% | -22.7% | +45.2% |
| Oct 2008 | Jan 2012 | 173 | 78.2% | -61.0% | +15.4% |
| Feb 2012 | Jul 2012 | 20 | 27.2% | -54.4% | +127.6% |
| Jul 2012 | Oct 2012 | 12 | 15.9% | -61.7% | +153.6% |
| Oct 2012 | Aug 2014 | 94 | 55.8% | -56.3% | +177.5% |
| Feb 2016 | Feb 2016 | 1 | 10.8% | +16.3% | +170.7% |
| Jun 2016 | Jul 2016 | 7 | 11.6% | +39.8% | +138.5% |
| Oct 2016 | Nov 2016 | 1 | 3.2% | +135.0% | +135.0% |
| Nov 2016 | Feb 2017 | 13 | 25.0% | +135.0% | +148.8% |
| Nov 2018 | Dec 2018 | 8 | 21.8% | -15.6% | +36.3% |
| Aug 2019 | Apr 2020 | 35 | 26.1% | +38.9% | +39.2% |
| Jun 2020 | Jun 2020 | 1 | 2.0% | -2.8% | +32.0% |
| Feb 2021 | Aug 2022 | 77 | 47.9% | -27.8% | +14.8% |
| Aug 2022 | Dec 2022 | 18 | 14.2% | +13.8% | +27.7% |
| Mar 2023 | May 2023 | 12 | 5.4% | +7.5% | +26.1% |
| Oct 2023 | Dec 2023 | 10 | 13.5% | -4.3% | +30.2% |
| Jan 2024 | Jan 2024 | 1 | 1.1% | -21.8% | +20.0% |
| Mar 2024 | Oct 2024 | 31 | 23.9% | -22.5% | +25.7% |
| Nov 2024 | Dec 2025 | 57 | 47.2% | -19.3% | +31.3% |
| Average | 30 | — | +0.8% | — |
Frequently Asked Questions
Is FOLD below its 200-week moving average?
No. Amicus Therapeutics Inc. (FOLD) is currently 34.2% above its 200-week moving average of $10.75. It would need to fall to $10.75 to cross below the line.
What is FOLD's 200-week moving average price?
Amicus Therapeutics Inc.'s 200-week moving average is $10.75 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when FOLD drops below its 200-week moving average?
FOLD has crossed below its 200-week moving average 19 times in our data. On average, buying at that moment produced a one-year return of +0.8%. These dips have historically been decent entry points. These episodes lasted 30 weeks on average.
Is FOLD a good value right now?
Here's what our data says about FOLD as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 98 (overbought). Free cash flow yield is 1.1%. Return on equity is -11.6%. Price-to-book is 16.4x. This is not a buy or sell recommendation — always do your own research.
How does FOLD compare to the S&P 500?
Over the past 17.9 years, $100 invested in FOLD would have grown to $139, compared to $644 for the S&P 500. That's 1.8% annualized vs 11.0% for the index. FOLD has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20